Kisspeptin is a family of neuropeptides encoded by the KISS1 gene (chromosome 1q32) that function as the principal upstream regulator of gonadotropin-releasing hormone (GnRH) secretion in the hypothalamus. The KISS1 gene produces a 145-amino acid prepropeptide that is cleaved into four biologically active isoforms sharing a common C-terminal RF-amide motif: kisspeptin-54 (KP-54, also called metastin), kisspeptin-14 (KP-14), kisspeptin-13 (KP-13), and kisspeptin-10 (KP-10). All isoforms bind and activate the KISS1 receptor (KISS1R, formerly GPR54), a Gq/11-coupled GPCR.
The reproductive significance of kisspeptin was established in 2003 when two independent research groups demonstrated that loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism and failure of puberty in humans. This discovery revealed kisspeptin as an obligate gatekeeper of reproductive function, sitting upstream of the entire hypothalamic-pituitary-gonadal (HPG) axis. Without functional kisspeptin signaling, GnRH neurons do not fire, gonadotropins are not released, and reproductive maturation does not occur.
Kisspeptin was originally identified in 1996 as a metastasis suppressor gene product in melanoma cells (hence the name "metastin" for KP-54), well before its reproductive role was understood. Today, kisspeptin is one of the most active areas of translational reproductive endocrinology research, with clinical trials exploring its use as an IVF oocyte maturation trigger, a diagnostic tool for GnRH neuronal function, and a potential therapeutic for hypothalamic amenorrhea, PCOS, and hypoactive sexual desire.
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Weeks 1–2 | 0.1 mg | 3 units0.03 mL |
| Weeks 3–8 | 0.2 mg | 6 units0.06 mL |
FrequencyOnce daily, subcutaneous.
For review — a different unit, route and purpose. The cited human work gave 0.3 to 10 nmol/kg intravenously to provoke a hormone response over minutes to hours; the daily subcutaneous milligram schedule in the chart follows a circulated research protocol. The concentration strip above the chart is calculated from the vial and water volume and is correct.
Unverified — the cited studies used single administrations or timed infusions, not a repeating daily course.
Kisspeptin has real human research behind it, which is what makes this chart misleading if read as a protocol: the Imperial College studies dosed in nanomoles per kilogram through an intravenous line under monitoring, and used it as a probe to trigger a measurable luteinising hormone response rather than as a treatment repeated for weeks. Converting those figures into a fixed daily milligram amount is not something the published work supports, so the rows are flagged for review. Athena lists one strength: a 10 mg vial made up with 3 mL gives about 3.33 mg/mL, so the 0.1 mg first step is 3 units and the 0.2 mg step is 6 units — both well inside one 50-unit syringe, and both small enough that a unit of measurement error moves the amount by a third. Kisspeptin acts upstream of the whole reproductive hormone axis, so an amount that does nothing measurable and one that produces a full response can be close together — another reason a weekly ladder is a poor description of it.
What this evidence establishes. Kisspeptin has genuine human research dosing, but it is expressed in nmol/kg rather than milligrams, was delivered intravenously under monitoring, and was used to provoke a measurable hormone response over minutes to hours — not as a repeated regimen. Converting those figures to a subcutaneous milligram dose is not something the published work supports.
Sources: Dhillo et al. — kisspeptin-54 administration studies in healthy volunteers
For educational and laboratory research purposes only. It does not provide medical advice, dosing recommendations, or instructions for human or veterinary use. Syringe units assume a U-100 syringe, on which 1 mL is 100 units and a 50-unit syringe holds 0.5 mL.
Kisspeptin signals through KISS1R on GnRH neurons in the hypothalamus, triggering a cascade that governs the entire reproductive hormone axis. The key mechanisms are:
Directly depolarizes GnRH neurons via KISS1R, stimulating pulsatile GnRH release into the hypothalamic-pituitary portal system
GnRH release triggers pituitary gonadotroph secretion of LH and FSH, which regulate gonadal steroidogenesis and gametogenesis
Kisspeptin expression increases at puberty onset, activating the dormant GnRH pulse generator. KISS1/KISS1R mutations prevent puberty entirely
Kisspeptin neurons express estrogen and androgen receptors, mediating both negative and positive sex steroid feedback on GnRH secretion
Arcuate kisspeptin neurons co-express neurokinin B (stimulatory) and dynorphin (inhibitory), forming the KNDy pulse generator that controls GnRH pulsatility
KP-54 can induce an LH surge sufficient for oocyte maturation in IVF, with a more physiological and shorter-duration LH exposure than hCG triggering
Clinical significance: Because kisspeptin acts one step upstream of GnRH rather than directly mimicking it, exogenous kisspeptin administration produces a more physiological, pulsatile hormone release pattern. This is particularly advantageous in IVF, where kisspeptin-triggered oocyte maturation may reduce ovarian hyperstimulation syndrome (OHSS) risk compared to hCG triggering.
Kisspeptin has been administered to humans in multiple clinical studies with a notable absence of serious adverse events. The following safety data is derived from published human clinical trials:
| Condition / Factor | Risk Level | Rationale |
|---|---|---|
| Hormone-sensitive cancers (breast, prostate, endometrial) | HIGH | Kisspeptin stimulates gonadotropin and sex steroid production. Contraindicated in conditions where increased estrogen or testosterone could promote tumor growth. |
| Pregnancy | HIGH | Effects on early pregnancy and placental function not well characterized. Kisspeptin/KISS1R expressed in placenta and endometrium. Excluded from clinical trials. |
| Precocious puberty | CONTRAINDICATED | Gain-of-function KISS1/KISS1R mutations are a known cause of central precocious puberty. Exogenous kisspeptin would worsen the condition. |
| Desensitization with continuous administration | MODERATE | Continuous (non-pulsatile) kisspeptin administration can desensitize the GnRH axis, paradoxically suppressing LH/FSH. Dosing pattern is critical. |
| Short plasma half-life (KP-10: ~4 min) | LOW (clinical limitation) | Rapid degradation limits therapeutic window. KP-54 has longer half-life (~28 min). Analogs like MVT-602 are being developed to address this. |
| Headache / facial flushing | LOW | Most commonly reported adverse events in clinical studies. Mild and transient. No serious adverse events attributed to kisspeptin in published trials. |
| Luteal phase insufficiency (IVF context) | MODERATE | Kisspeptin-triggered LH surge is shorter than hCG, potentially leading to insufficient corpus luteum support. Luteal phase supplementation recommended. |
| Polycystic ovary syndrome (PCOS) | MODERATE (under study) | PCOS patients have elevated kisspeptin and LH pulsatility. Exogenous kisspeptin may worsen hyperandrogenism. Being actively studied with careful dose optimization. |
| Human safety data | FAVORABLE (limited) | No increased adverse events reported across multiple published human clinical studies. Safety profile appears favorable, but long-term data is limited. |
| Overall adverse event profile | WELL-TOLERATED | Clinical studies report excellent tolerability. No dose-limiting toxicities identified. Most common: mild injection site reactions, transient headache, flushing. |
FDA: Kisspeptin is not FDA-approved for any therapeutic indication. It is classified as an investigational compound being studied in Phase 2 clinical trials for reproductive applications, primarily IVF oocyte maturation triggering and fertility restoration.
Clinical Development: Multiple KISS1R agonists are in development. MVT-602 (Myovant Sciences/Sumitomo Pharma) is a synthetic kisspeptin receptor agonist with prolonged pharmacokinetics being evaluated in clinical trials. TAK-448 (Takeda) has been studied in both women and men. Small molecule KISS1R antagonists are in preclinical development for conditions requiring HPG axis suppression.
Research Status: Kisspeptin has robust human pharmacological data from multiple academic clinical trials, primarily conducted at Imperial College London and the University of Edinburgh. It has a well-characterized mechanism and a favorable safety profile in published studies. However, it has not yet completed the Phase 3 trials required for regulatory approval.
Key distinction: Kisspeptin represents one of the most significant discoveries in reproductive endocrinology in the past 25 years. Its identification as the gatekeeper of puberty and fertility fundamentally changed understanding of the HPG axis. The translational pipeline is active, but the compound's very short half-life has been a barrier to therapeutic development, driving interest in longer-acting analogs.
Test your understanding of kisspeptin's role in reproductive endocrinology, its mechanism, and clinical applications.
This profile is for educational and research purposes only. It is not medical advice, and nothing on it is a protocol, a recommendation, or an instruction for use in a person or an animal.
Athena Peptides Education does not prescribe, sell, or recommend any compound. Compounds discussed here are for laboratory research only and are not for human consumption. Always consult a qualified physician before making any decision about your health.